Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy

描述（由申请人提供）：癌症治疗中的抗血管生成方法在临床前小鼠模型中显示出巨大的潜力，但迄今为止这种潜力尚未完全实现 在人类癌症治疗中。这个为期2天的会议名为"靶向VEGF介导的肿瘤血管生成在癌症治疗中的作用"，将于2014年6月19 - 20日在纽约市由纽约科学院提出。该会议将探讨我们对影响现有抗血管生成癌症疗法疗效的机制的理解，包括讨论正在进行验证的生物标志物，这些生物标志物可能预测耐药性和总体临床结果，目的是改善当前的治疗方法并开发新的抗血管生成癌症策略。预计此次活动将召集250名与会者，包括学术界、工业界和政府的基础科学家和临床研究人员;肿瘤学家;制药战略家;以及监管专家。本次会议的三个主要目标是：（i）通过讲座、主旨演讲、互动辩论和网络活动提供中立论坛，以讨论靶向血管生成的癌症治疗的当前障碍和新兴创新方法，例如固有和获得性抗性、补偿性血管生成信号传导、血管正常化、免疫调节、肿瘤类型、阶段和环境相关的药物反应性，生物标志物，以预测反应性和耐药性，药物安全性和联合治疗方法，以提高疗效;（ii）展示和鼓励早期职业，女性和代表性不足的少数民族研究人员通过简短的谈话，海报演示/奖品，旅行奖学金，职业指导活动和折扣注册的参与;及（iii）促进来自各界别的国际研究人员之间的合作，以促进将研究成果转化为更安全及更有效的癌症治疗方法。会议目标与国家癌症研究所（NCI）的使命保持一致，以支持与癌症相关的基础科学和临床学科的教育，支持癌症控制研究项目，并鼓励行业进行癌症研究。此外，NCI收集和传播癌症信息的具体目标将通过在《纽约科学院年鉴》上发表一份会议后的、持久的、开放获取的、符合第508条的会议报告来实现，该报告将向全球研究和医学界传播会议上交流的科学知识和想法。鉴于在不同的研究领域（例如，血管形成和免疫应答）和各种科学方法（例如，动物模型和人类临床试验）。因此，在所有血管生成利益相关者之间对这一新信息进行合作检查对于指导该领域的研究具有重要价值-特别是在潜在的创新治疗方法方面，例如规避耐药性的方法和开发用于识别反应患者的生物标志物。

DESCRIPTION (provided by applicant): Anti-angiogenic approaches in cancer therapy show great potential in preclinical mouse models, yet to date this potential has not been fully realized in human cancer therapy. This 2-day conference titled, "Targeting VEGF- mediated Tumor Angiogenesis in Cancer Therapy," will be presented by the New York Academy of Sciences on June 19-20, 2014, in New York City. The conference will explore our understanding of the mechanisms impacting the efficacy of existing anti-angiogenic cancer therapeutics, including discussions on biomarkers undergoing validation that may predict resistance and overall clinical outcome, with the goals of improving current treatments and developing new anti-angiogenic strategies for cancer. It is anticipated that this event will convene 250 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; oncologists; pharmaceutical strategists; and regulatory experts. The three central aims of this conference are to: (i) provide a neutral forum through lectures, a keynote presentation, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to angiogenesis-targeted cancer therapy, such as inherent and acquired resistance, compensatory angiogenic signaling, vascular normalization, immune modulation, tumor-type, -stage and -environment related drug responsiveness, biomarkers to predict responsiveness and resistance, drug safety, and combination therapy approaches for improved efficacy; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations/prizes, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboration among international investigators from all sectors to promote the translation of research into safer and more efficient cancer therapeutics. The conference goals align well with the mission of the National Cancer Institute (NCI) to support education in fundamental sciences and clinical disciplines relating to cancer, champion research projects in cancer control, and encourage cancer research by industry. In addition, the NCI's specific goal of collecting and disseminating information on cancer will be met through the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. This conference is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., blood vessel formation and immune response) and from varied scientific approaches (e.g., animal models and human clinical trials). A collaborative examination of this new information among all angiogenesis stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential innovative therapeutic approaches, such as ways to circumvent resistance and the development of biomarkers for identifying responsive patients.